ADC Therapeutics SA

ADC Therapeutics SA is a biotechnology company focused on developing antibody drug conjugates (ADCs) for the treatment of cancers. Its flagship product is ZYNLONTA, a CD19-directed ADC that has received accelerated approval from the U.S. FDA, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also investigating ZYNLONTA in earlier lines of DLBCL and indolent lymphomas such as follicular lymphoma and marginal zone lymphoma, both as a single agent and in combination therapies. Additionally, ADC Therapeutics has a preclinical pipeline targeting antigens like Claudin-6, NaPi2b, PSMA, and ASCT2.

ADC Therapeutics SA is listed on the New York Stock Exchange (NYSE) under the ticker symbol ADCT. The company's shares are traded in US Dollars (USD), as it is listed in the United States region. Despite being headquartered in Switzerland, the company chose to list on a major US exchange, which is common for biotech firms seeking access to deep capital markets and a broad investor base.

ADC Therapeutics operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and manufacturing of specialized pharmaceutical products, particularly antibody drug conjugates (ADCs) for oncology. As a specialty drug manufacturer, ADC Therapeutics focuses on targeted therapies that deliver cytotoxic agents directly to cancer cells, aiming to improve efficacy and reduce side effects compared to traditional chemotherapy.

ADC Therapeutics SA is headquartered in Epalinges, Switzerland, and was incorporated in 2011. The company operates primarily in Switzerland and the United States, but its products and clinical trials have a global reach. ZYNLONTA has received regulatory approvals in the United States, Europe, and China, indicating that the company serves patients in these major markets. ADC Therapeutics is also seeking to expand ZYNLONTA into international markets and earlier lines of therapy, suggesting a strategy to broaden its geographic presence and patient access.

ADC Therapeutics generates revenue primarily through the commercialization of its approved product, ZYNLONTA, which is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). As a biotechnology company, its business model involves investing heavily in research and development to create novel antibody drug conjugates (ADCs). The company's pipeline includes both clinical-stage and preclinical candidates targeting various cancers. Revenue is derived from product sales, and potentially from partnerships or licensing agreements, though the provided data does not specify current partnerships. The company also conducts clinical trials, such as the LOTIS-5 confirmatory Phase 3 trial and LOTIS-7 Phase 1b trial, to support label expansions and combination therapies, which could drive future revenue growth.